[Phenotype of infantile epileptic spasm syndrome in pyridoxin-dependent epilepsy]

Xianru Jiao1,2, Pan Gong2, Yue Niu1

  • 1Department of Pediatrics, Peking University People's Hospital, Beijing 100044, China.

Insights

Pyridoxine-dependent epilepsy (PDE) can present as infantile epileptic spasm syndrome (IESS). Early pyridoxine treatment is crucial for seizure control and improved prognosis in these patients with ALDH7A1 variants.

Area of Science:

  • Pediatric Neurology
  • Metabolic Disorders
  • Epilepsy Genetics

Context:

  • Infantile epileptic spasm syndrome (IESS) is a severe epilepsy syndrome in infants.
  • Pyridoxine-dependent epilepsy (PDE) is an inherited metabolic disorder caused by ALDH7A1 gene variants.
  • IESS is a rare but recognized phenotype of PDE.

Purpose:

  • To analyze the clinical characteristics, treatment responses, and prognostic factors of pediatric patients with PDE presenting with IESS.
  • To investigate the correlation between ALDH7A1 genotype and clinical outcomes in these patients.

Summary:

  • Five patients with PDE and IESS phenotype, confirmed ALDH7A1 variants, were analyzed.
  • High-dose pyridoxine effectively controlled seizures in four patients, normalizing EEG.
  • Prognosis was linked to diagnostic delay, seizure control, brain injury, and specific ALDH7A1 variants, particularly deletions.

Impact:

  • Highlights IESS as a potential phenotype of PDE, emphasizing the importance of early diagnosis and pyridoxine treatment.
  • Identifies diagnostic delays, seizure severity, brain injury, and ALDH7A1 deletion variants as indicators of poor prognosis.
  • Informs clinical management strategies for PDE patients with IESS phenotype to improve neurodevelopmental outcomes.
Abstract

Related Concept Videos

Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
304
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
140
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
263
Arteries of the Lower Limbs01:24

Arteries of the Lower Limbs

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
178
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
148
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
338